nf2 neurofibromas - Sports Zone
CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ... Healio: FDA approves Koselugo for neurofibromatosis type 1 with plexiform neurofibromas in adults FDA approves Koselugo for neurofibromatosis type 1 with plexiform neurofibromas in adults Targeted Oncology: FDA Grants Fast Track Designation to PAS-004 for NF1-Associated Plexiform Neurofibromas The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas causing significant morbidity. The New England Journal of Medicine: Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas Neurofibromatosis type 1 is a common genetic disorder that is characterized by multiple manifestations including tumors of the nervous system.
Understanding the Context
1,2 Plexiform neurofibromas develop in 20 to 50% of ... News Medical: Study discovers origin of neurofibromas that develop throughout the skin of NF1 patients